FDA staff highlight neurological safety concerns with Durect's pain drug

Days after stinging trial failure forced the California company to abandon its psoriasis program, FDA staff reviewers issued a review that highlighted the risk of neurological side effects with Durect Corp’s long-acting anesthetic, posimir, for patients with post-surgical analgesia.